

Special Issue

Crosstalk between Cancer-Associated Fibroblasts and Cancer Cells

Message from the Guest Editor

Among components of the tumor microenvironment (TME), the heterogeneous population of cancer-associated fibroblasts (CAFs) plays a pivotal role, providing a constant stimulation for tumor cells and other components of the TME through cell-cell contact and the production of soluble mediators. CAFs strongly contribute to the proliferative, pro-inflammatory, pro-angiogenic, pro-invasive, and pro-metastatic properties that TME exerts on cancer. The purpose of this special issue is to stimulate the presentation of scientific data revealing the molecular mechanisms underlying the crosstalk between CAFs and tumor cells. The discovery of the specific functions of CAF subpopulation on cancer cell properties like, among the others, cancer onset and progression to late stages of the disease, evasion from immune surveillance, and resistance to chemotherapy, can be used to develop novel strategies to indirectly disrupt cancer cell interplay and contribute to the development of a CAF-based strategy for a precision therapy to be combined with conventional anticancer approaches.

Guest Editor

Dr. Lucia Magnelli

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale G.B. Morgagni, 50-50134 Firenze, Italy

Deadline for manuscript submissions

closed (15 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/121427

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)